Stem Cell Therapy International, Inc. Form 8-K August 05, 2008

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

### FORM 8-K

### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the

**Securities Exchange Act of 1934** 

Date of Report (Date of earliest event reported): AUGUST 5, 2008

# STEM CELL THERAPY INTERNATIONAL, INC.

(Exact Name of Registrant as Specified in Its Charter)

Nevada 000-51931 88-0374180

### Edgar Filing: Stem Cell Therapy International, Inc. - Form 8-K

(State or other jurisdiction of (Commission File Number) (I.R.S. Employer incorporation or organization)

2203 N. Lois Avenue, 9<sup>th</sup> Floor, Tampa, FL 33607

(Address of principal executive offices zip code)

(813) 600-4088

(Registrant s telephone number, including area code)

Not applicable

(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

### ITEM 4.01 CHANGES IN REGISTRANT S CERTIFYING ACCOUNTANT.

The Company has recently engaged Brimmer, Burek, Keelan LLP, Certified Public Accountants, Tampa, FL, as its new independent accountants and who will audit the financial statements for the Company s Annual Report on Form 10K for the year ended March 31, 2009 and review the quarterly consolidated financial statements.

### **SIGNATURE**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STEM CELL THERAPY INTERNATIONAL, INC.

By: /s/ Andrew J. Norstrud Name: Andrew J. Norstrud Title: Chief Financial Officer

Date: August 5, 2008